- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials Sponsored by Friends of Dana-Farber, Dana-Farber Cancer Institute
Total 1205 results
-
Dana-Farber Cancer InstituteTerminatedBreast CancerUnited States
-
Dana-Farber Cancer InstituteCompletedWeight Loss Program After Cancer DiagnosisUnited States
-
Dana-Farber Cancer InstituteWithdrawnSquamous Cell Carcinoma of the OropharynxUnited States
-
Dana-Farber Cancer InstituteWithdrawnLangerhans Cell Histiocytosis
-
Dana-Farber Cancer InstituteCompleted
-
Dana-Farber Cancer InstituteCompletedSarcoma | Neuroblastoma | Wilms Tumor | Pediatric Solid TumorUnited States
-
Dana-Farber Cancer InstituteTerminated
-
Dana-Farber Cancer InstituteCompletedMultiple Myeloma | Hodgkin's Lymphoma | Non-Hodgkin's LymphomaUnited States
-
Dana-Farber Cancer InstituteCompleted
-
Dana-Farber Cancer InstituteCompletedMyelodysplastic Syndromes | Non-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Graft Versus Host Disease | Hodgkin's DiseaseUnited States
-
Dana-Farber Cancer InstituteAstraZenecaActive, not recruitingNon-Small Cell Lung CancerUnited States
-
Dana-Farber Cancer InstituteAbbVieActive, not recruitingBlastic Plasmacytoid Dendritic Cell NeoplasmUnited States
-
Dana-Farber Cancer InstituteBayerActive, not recruitingThyroid CancerUnited States
-
Dana-Farber Cancer InstituteAstraZenecaTerminatedRecurrent Ovarian Carcinoma | Recurrent Cervical Carcinoma | Recurrent Endometrial Cancer | Metastatic Endometrial Cancer | Metastatic Cervical Cancer | Recurrent Vaginal Cancer | Recurrent Vulvar Cancer | Metastatic Ovarian Cancer | Recurrent Gynecological Cancer | Metastatic Vaginal Cancer | Metastatic...United States
-
Dana-Farber Cancer InstitutePfizerCompletedHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast | Hormone Receptor (HR)-Positive Breast CancerUnited States
-
Dana-Farber Cancer InstituteNovartisCompleted
-
Dana-Farber Cancer InstituteNovartisCompletedMultiple Myeloma in RelapseUnited States
-
Dana-Farber Cancer InstituteNovartisCompletedMucosal Melanoma | Acral/Lentiginous Melanoma | Chronically Sun Damaged MelanomasUnited States
-
Dana-Farber Cancer InstituteBayerWithdrawn
-
Dana-Farber Cancer InstituteNovartisRecruitingProstate Cancer | Metastatic Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States
-
Dana-Farber Cancer InstitutePfizerRecruiting
-
Dana-Farber Cancer InstitutePfizerRecruitingBladder Cancer | Muscle Invasive Bladder CancerUnited States
-
Dana-Farber Cancer InstitutePfizerRecruitingPancreatic Cancer | Solid Tumors | Lung Cancer Squamous Cell | Head & Neck CancerUnited States
-
Dana-Farber Cancer InstituteMedtronicActive, not recruiting
-
Dana-Farber Cancer InstitutePfizerActive, not recruitingBreast CancerUnited States
-
Dana-Farber Cancer InstituteCelgeneActive, not recruitingLangerhans Cell Histiocytosis (LCH) | Histiocytoses Erdheim-chester Disease | Histiocytic Sarcoma (HS)United States
-
Dana-Farber Cancer InstituteNovartisActive, not recruitingAcute Lymphoblastic Leukemia ALLUnited States
-
Dana-Farber Cancer InstituteAstraZenecaWithdrawnUveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Recurrent Metastatic MelanomaUnited States
-
Dana-Farber Cancer InstitutePfizerActive, not recruiting
-
Dana-Farber Cancer InstituteNovartisCompletedEverolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL (CRAD001NUS175T)Acute Lymphoblastic LeukemiaUnited States
-
Dana-Farber Cancer InstituteExelixisTerminatedSkin Cancer | Merkel Cell CarcinomaUnited States
-
Dana-Farber Cancer InstituteNovartisActive, not recruiting
-
Dana-Farber Cancer InstitutePfizerCompletedBreast Cancer Stage IV | Unresectable Locally Advanced Invasive Breast Cancer | Metastatic Invasive Breast CancerUnited States
-
Dana-Farber Cancer InstituteAbbVieCompletedWaldenstrom MacroglobulinemiaUnited States
-
Dana-Farber Cancer InstitutePfizerActive, not recruiting
-
Dana-Farber Cancer InstituteAmgenTerminatedLymphoma | Autonomic Imbalance | Cancer SurvivorshipUnited States
-
Dana-Farber Cancer InstituteAllerganTerminatedPancreatic CancerUnited States
-
Dana-Farber Cancer InstituteBiogenCompletedGraft Versus Host DiseaseUnited States
-
Dana-Farber Cancer InstituteBayerWithdrawn
-
Dana-Farber Cancer InstituteBeiGeneRecruitingChronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL)United States
-
Dana-Farber Cancer InstituteAbbVieRecruitingB-Cell Lymphoma | B-cell Acute Lymphoblastic Leukemia | ALLUnited States
-
Dana-Farber Cancer InstituteAstraZenecaRecruiting
-
Dana-Farber Cancer InstituteAbbVieRecruiting
-
Dana-Farber Cancer InstituteAstraZenecaWithdrawnChronic Lymphocytic Leukemia | Small Lymphocytic LymphomaUnited States
-
Dana-Farber Cancer InstituteServierActive, not recruitingAcute Lymphoblastic Leukemia, PediatricUnited States, Canada
-
Dana-Farber Cancer InstitutePfizerActive, not recruiting
-
Dana-Farber Cancer InstitutePfizerCompleted
-
Dana-Farber Cancer InstituteBayerTerminatedSolid Tumor | Hand-Foot Skin Reaction (HFSR)United States
-
Dana-Farber Cancer InstituteAstraZenecaSuspendedMesotheliomaUnited States
-
Dana-Farber Cancer InstituteAstraZenecaActive, not recruitingUterine CancerUnited States